A carregar...
The Why, what, and How of the New FACT standards for immune effector cells
Novel cellular therapies outside of traditional hematopoietic stem cell transplantation or hematopoietic progenitor cell (HPC) therapy are currently under evaluation in clinical trials across the United States and around the world. Several cellular products, e.g., CD19-directed Chimeric Antigen Rece...
Na minha lista:
| Publicado no: | J Immunother Cancer |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5394615/ https://ncbi.nlm.nih.gov/pubmed/28428885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0239-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|